Dorzolamide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Dorzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Dorzolamide is a topical carbonic anhydrase inhibitor used to lower intraocular pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may also be effective for primary hereditary glaucoma, with a prediction score of 99.99%, but this specific indication currently has no directly matching clinical trials or published literature — the case rests entirely on mechanistic extrapolation from the drug’s well-established use in open-angle glaucoma.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / ocular hypertension (topical carbonic anhydrase inhibitor) — no formal indication text available in this evidence pack |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold (flagged internally as “Research Question”) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a data gap). Based on known pharmacology, Dorzolamide is a topical carbonic anhydrase II (CA-II) inhibitor applied to the ciliary body epithelium, where it reduces aqueous humour production and thereby lowers intraocular pressure — this is its well-established, long-standing mechanism in glaucoma management.
Primary hereditary glaucoma (largely early-onset open-angle or congenital genetic subtypes) shares the same underlying pathophysiology as typical open-angle glaucoma: impaired aqueous humour outflow leading to elevated intraocular pressure. On that basis, Dorzolamide’s IOP-lowering mechanism is plausibly transferable.
However, this specific ontology term has no direct trial or literature support — the evidence is inferred indirectly through the large body of evidence for standard open-angle glaucoma (see ranks 6–7 in the underlying dataset, both graded L1/S3/Proceed with Guardrails), rather than any study conducted in a hereditary or congenital glaucoma population. Notably, safety and dosing in paediatric/infant populations — who make up a meaningful share of hereditary/congenital glaucoma cases — remain unvalidated for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Dorzolamide currently holds no marketing authorisation in the UK evidence pack on record (0 licences; market status: not marketed). No product-level licence details are available to summarise.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (primary hereditary glaucoma) has no direct clinical trial or literature evidence — support is purely mechanistic, extrapolated from a related but pathologically distinct condition (typical open-angle glaucoma). This does not meet the threshold to proceed even under guardrails.
To proceed, the following is needed:
- TFDA/MHRA product labelling — warnings, precautions and contraindications (currently a blocking data gap; required before any safety pre-assessment)
- Confirmed mechanism of action data from DrugBank or equivalent source
- Dedicated clinical evidence in a hereditary/congenital glaucoma population, including paediatric safety data
- Confirmation of UK marketing authorisation status, given the current pack shows the drug as not marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.